• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

N-Power Medicine Closes $32M to Expand Community Oncology Research

by Fred Pennic 09/01/2026 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
N-Power Medicine Closes $32M to Expand Community Oncology Research

What You Should Know

  • Oncology drug development platform N-Power Medicine closed a $32M Series B financing round to scale its community oncology clinical research network and expand adoption of its Prospective External Control Arms (ProECA) technology.
  • The financing features Labcorp Venture Fund as a new strategic investor, alongside continued participation from Merck Global Health Innovation Fund (Merck GHI), Innovatus Capital Partners, and a leading U.S.-based biotechnology investor.
  • Solves a critical clinical trial bottleneck by generating trial-grade, standalone prospective external control arms directly from routine community cancer care, significantly reducing the need for traditional patient randomization, decreasing trial sample size requirements, and compressing drug development timelines.
  • N-Power’s initial ProECA program in non-small cell lung cancer (NSCLC) is active across more than 40 clinical sites spanning multiple large community health systems, currently used by biopharma sponsors to accelerate early-phase and Phase 4 post-market studies.
  • Pipeline expansion includes the upcoming rollout of ProECA platforms for colorectal cancer and prostate cancer later this year.

Generating Regulatory-Grade External Controls in Routine Care

N-Power Medicine embeds research operations directly into everyday community oncology workflows, allowing standard-of-care patients to contribute to clinical evidence without disrupting routine practice.

The new capital will accelerate the expansion of its community research footprint and drive broader biopharma adoption of ProECA, its proprietary Prospective External Control Arm platform:

  • Trial-Grade Prospective Harmonization: Unlike retrospective chart reviews, ProECA prospectively mirrors active clinical trial protocols—capturing protocol-aligned inclusion/exclusion criteria, next-generation sequencing (NGS), standardized imaging intervals, and bio-sample collection schedules directly from routine patient visits.
  • De-Risking Early-Stage Pipelines: Enables biopharma sponsors to run smaller, single-arm or augmented Phase 2 studies, accelerating Phase 2-to-Phase 3 transition decisions and Phase 4 post-marketing commitments while reducing the number of enrolled control subjects needed.
  • Active NSCLC Deployment & Multi-Tumor Expansion: N-Power’s initial non-small cell lung cancer (NSCLC) ProECA is active across more than 40 community oncology sites within regional health systems, with planned rollout into colorectal cancer and prostate cancer cohorts later this year.

“We’ve built a model that creates value for drug developers, community oncologists, and cancer patients. By bringing prospective external control arm programs directly into everyday cancer care, we dramatically speed up drug development while giving many more oncologists and patients access to research and innovative therapies,” said Dr. Mark Lee, co-founder and CEO of N-Power Medicine. “With Labcorp Venture Fund joining our existing investors, this financing lets us scale and set a new standard for how oncology drug development gets done.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Oncology, Oncology Platform

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |